Sign in
4

Changes in Ownership

BioXcel Therapeutics, Inc. Filed Acc 0001104659-24-100746

Chief Commercial Officer sold 215 shares at $0.69 ($149)

  • Chief Commercial Officer acquired 750 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Wiley Matthew T. · Chief Commercial Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2024-09-15 Exercise or conversion : show line 1 in the form 10b5-1 +750 4,248 D
2024-09-16 Sale : show line 2 in the form 10b5-1 −215 $0.69 $149 4,033 D
Open-market sales · 215 sh · avg $0.69 · $149

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-09-15 Exercise or conversion : show line 3 in the form 10b5-1 Restricted Stock Units −750 7,500 D
Loading xslF345X05/tm2424255-5_4seq1.xml…